Cardiff Oncology (NASDAQ: CRDF) — Perfil da empresa, notícias e dados financeiros
Cardiff Oncology is a biotechnology firm developing targeted cancer treatments, focusing on unmet needs in colorectal, pancreatic, and prostate
Cardiff Oncology
Cardiff Oncology (NASDAQ:CRDF) is a biotechnology firm focused on developing new treatment options for cancer patients. Concentrating on oncology, the company leverages scientific innovations to create targeted solutions aiming to address the unmet needs within the cancer treatment landscape. Cardiff Oncology is particularly known for its commitment to advancing its lead drug candidate, onvansertib, through various phases of clinical trials in combination with standard-of-care therapies. The objective is to improve patient outcomes in cancers with significant unmet need, including colorectal, pancreatic, and prostate cancers. Its projects are designed to disrupt cancer cell growth and resistance, demonstrating the company's dedication to pushing the boundaries of cancer treatment. Through strategic partnerships and ongoing research, Cardiff Oncology seeks to unlock new possibilities in oncology, providing hope and new options for patients and their families.
Resumo
Operações
Produtos e/ou serviços de Cardiff Oncology
- Onvansertib, a PLK1 inhibitor being developed for the treatment of KRAS-mutated colorectal cancer, showing promise in combination with standard-of-care treatments.
- Clinical trials for Onvansertib targeting Acute Myeloid Leukemia (AML), exploring its effectiveness in halting cancer cell progression.
- Studies of Onvansertib in Castrate-Resistant Prostate Cancer (CRPC), investigating its ability to enhance the effectiveness of androgen deprivation therapy.
- Research into Onvansertib's applications in Non-Small Cell Lung Cancer (NSCLC), focusing on patients with specific genetic mutations.
- Development of Onvansertib for treatment of Triple-Negative Breast Cancer (TNBC), aiming to offer a new therapeutic option for this difficult-to-treat cancer type.
- Investigation into the combination of Onvansertib with targeted therapies across various cancer types, seeking synergistic effects that improve treatment outcomes.
equipe executiva do Cardiff Oncology
- Mani MohindruPresident, CEO & Director
- Roger SidhuChief Medical Officer
- Joshua MuntnerChief Financial Officer
- Ajay AggarwalChief Operating Officer
- Brigitte LindsayChief Accounting Officer
- Tod SmealChief Scientific Officer
- Elizabeth AndersonVP of Finance & Administration
Principais indicadores financeiros
Resultados divulgados pela Cardiff Oncology, em USD.
- Cap. de mercado
- 69,8 mi
- Receita (TTM)
- 508 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 593 mil | -49 mi | -45,9 mi | |
| 683 mil | -48,7 mi | -45,4 mi | |
| 488 mil | -45,4 mi | -41,4 mi | |
| 386 mil | -39,9 mi | -38,7 mi |